Theialife Announces Positive Type C Meeting with FDA for ND10 in Progressive Myopia
Company and Agency align on pivotal program design, endpoint strategy and study duration, providing clear path forward for ND10 development
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


